CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
ABT-450 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01306617
NCT01306617Phase 2Completed
CompareCT.gov

An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

AbbVie (prior sponsor, Abbott)·interventional·Posted Mar 2, 2011·Updated Jan 8, 2015

In Brief

A Phase 2 clinical trial evaluating ABT-450, ABT-333, and 2 other interventions for Chronic Hepatitis C Infection and 2 related conditions. Completed, enrolled 50 participants across 11 sites.

Detailed Summary

The purpose of this study is to evaluate the antiviral activity, safety, and pharmacokinetics of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-333 (also known as dasabuvir) and ribavirin (RBV) in treatment-naïve and non responder participants with genotype 1 chronic hepatitis C virus (HCV) infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C Infection, Hepatitis C, Hepatitis C Virus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2, 2011
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.3 years ago

Interventions

ABT-450drug

tablets

ABT-333drug

tablets

ribavirindrug

tablets

ritonavirdrug

capsules